Traditional cancer research involves the study of cancer biology at the cellular, organ, and systemic level. In light of the technological developments in engineering, physics, lasers, imaging systems, biosensing and bioMEMS devices, advanced microscopy systems, drug delivery systems and nanotechnology, the Biomedical Technology Program (BTP) is organized with the goals of capitalizing on the tools and technologies developed by engineering and physical scientists by applying these devices and concepts towards the overall reduction of cancer morbidity and mortality. Currently, the BTP incorporates five scientific themes that capture the breadth of expertise and technologies available to the program. The five themes are: (1) Research and Diagnostic Technologies, (2) Technologies for Whole Body/Organ Imaging, (3) Technologies for Cancer Therapy, (4) Biomarker Discovery and Development, and (5) Biosensing Technologies. The BTP has 34 members with expertise across broad areas of engineering science, physical science and medical science. The BTP includes members from eleven different research and academic departments and four different schools and research centers at UC Davis and Lawrence Livermore National Laboratory (LLNL). This includes the College of Engineering (in particular the Departments of Biomedical Engineering and Mechanical and Aeronautical Engineering), the School of Medicine (in particular Radiology, Radiation Oncology, Internal Medicine, General Surgery, Neurological Surgery), the School of Veterinary Medicine, and LLNL. The BTP also includes members who are primarily clinicians, who play an important role in ensuring the program is addressing cancer-relevant questions, and a critical role in helping technical members of the program move new technologies into successful early phase clinical testing in patients. Thus, the expertise of our members spans a wide range of scientific disciplines and fields bridging from the engineering and physical sciences to the medical and veterinary sciences. PROGRAM ASPECTS Co-leaders: Simon Cherry, PhD; Laura Marcu, PhD Members: 34 Total Grant Funding (ADC): $7.8 million Total Peer-Reviewed Funding (ADC): $7.2 million Total NCI funding (ADC): $3.0 million Total No. Publications: 644 Inter-programmatic publications: 235 (37%) Intra-programmatic publications: 121 (19%) Multi-institutional publications: 262 (41%)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA093373-14
Application #
9148414
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
14
Fiscal Year
2016
Total Cost
$33,309
Indirect Cost
$12,093
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589
Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91

Showing the most recent 10 out of 836 publications